Bruton tyrosine kinase inhibitors (BTKi) have revolutionised the treatment of chronic lymphocytic leukaemia (CLL). Cardiovascular (CV) adverse events associated with BTKi therapy may interfere with continuation of best possible care, induce life-threatening CV complications or lead to long-term morbidity including worse CLL-related outcomes if optimal BTKi treatment is withheld.1, 2 Correct understanding, interpretation and management of BTKi-related CV adverse events are required and should be placed within the context of the overall care of the individual patient. We aim to provide practical management recommendations for BTKi-associated cardiac toxicity to enhance maintenance on BTKi therapy with minimal disruption.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.